{"text": ["Novartis", "abandons", "effort", "for", "U.S.", "approval", "of", "biosimilar", "rituximab"], "created_at": "2018-11-02 23:27:56"}
{"text": ["Novartis", "data", "at", "ASH", "and", "SABCS", "show", "strength", "of", "pipeline", "and", "portfolio", "in", "hematology", "and", "oncology"], "created_at": "2018-11-02 21:27:00"}
{"text": ["AbbVie's", "(ABBV)", "Q3", "Earnings", "Beat", "Estimates,", "2018", "EPS", "View", "Up"], "created_at": "2018-11-02 18:12:13"}
{"text": ["AbbVie's", "(ABBV)", "Q3", "Earnings", "Beat", "Estimates,", "2018", "EPS", "View", "Up"], "created_at": "2018-11-02 18:12:13"}
{"text": ["Conatus'", "(CNAT)", "Q3", "Loss", "In", "Line,", "Revenues", "Lag", "Estimates"], "created_at": "2018-11-02 18:09:17"}
{"text": ["Conatus'", "(CNAT)", "Q3", "Loss", "In", "Line,", "Revenues", "Lag", "Estimates"], "created_at": "2018-11-02 18:09:17"}
{"text": ["Conatus&apos;", "(CNAT)", "Q3", "Loss", "In", "Line,", "Revenues", "Lag", "Estimates"], "created_at": "2018-11-02 16:30:04"}
{"text": ["A", "Look", "at", "Merck\u2019s", "Diabetes", "and", "Women\u2019s", "Health", "Business"], "created_at": "2018-11-02 14:30:18"}
